SBIR/STTR Research Award

THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR THE IMPROVEMENT OF THIS VERY IMPORTANT CLASS OF ANTIMICROBIALS.

Award identifier c3a36201666c5d7190758dd39dcf3008e3fbdf936347c40e629db706eabc8e3eAwarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1985

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
H. G. Pars Pharmaceutical Labo
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR THE IMPROVEMENT OF THIS VERY IMPORTANT CLASS OF ANTIMICROBIALS. THE VARIED USEFUL ATTRIBUTES OF THE NEW OXACEPHALOSPORIN MOXALACTAM, NAMELY BROAD SPECTRUM OF ACTIVITY, FAVORABLE PHARMACOKINETIC PROFILE, AND STABILITY, PROMPTS US TO PROPOSE THE SYNTHESIS AND EVALUATION OF A RELATED OXACEPHALOSPORIN STRUCTURE. RECENTLY WE SYNTHESIZED A NOVEL TRICYCLIC OXACEPHALOSPORIN WHICH IS EXPECTED TO LEAD TO A SERIES OF COMPOUNDS FROM WHICH ANTIMICROBIAL ACTIVITY IS EXPECTED. WE NOW PROPOSE THE SYNTHESIS OF A SERIES OF THESE ANALOGS AND THEIR EVALUATION AGAINST A BROAD SPECTRUM OF BACTERIA. BASED UPON PRELIMINARY STRUCTURAL ANALYSIS, THIS NEW OXACEPHALOSPORIN APPEARS TO BE RELATED CLOSELY TO PENICILLINS, AND THEREFORE WE ANTICIPATE SIGNIFICANT GRAM-POSITIVE ACTIVITY IN ADDITION TO THE GRAM-NEGATIVE ACTIVITY CEPHALOSPORINS GENERALLY POSSESS. BY ANALOGY WITH MOXALACTAM, WE ANTICIPATE RESISTANCE TO BACTERIAL ENZYMATIC INACTIVATION, AN ATTRIBUTE WHICH IS INCREASINGLY IMPORTANT DUE TO WIDESPREAD RESISTANCE TO CURRENT ANTIBIOTICS. THIS PHASE I PROGRAM WILL PROVIDE THE BASIS FOR THE DEVELOPMENT OF STRUCTURES WITH IMPROVED ANTIBACTERIAL PROPERTIES AND WILL PROVIDE STRUCTURE ACTIVITY INFORMATION IN THE NEW CLASS OF OXACEPHALOSPORINS REPRESENTED BY MOXALACTAM.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.